Pharmafile Logo
Pharmafocus logo
Advanced Search

drisapersen

Showing 3 posts of 3 posts found.

FDA

FDA says no to BioMarin’s Duchenne Muscular Dystrophy drug

January 14, 2016
Medical Communications, Sales and Marketing BioMarin, Duchenne Muscular Dystrophy, FDA, Kyndrisa, drisapersen

The FDA has rejected BioMarin’s Duchenne Muscular Dystrophy (DMD) drug Kyndrisa, saying there was not enough evidence that the drug …

News
Biomarin image

BioMarin to buy Prosensa in $840 million deal

November 25, 2014
Sales and Marketing BioMarin, Prosensa, drisapersen, dystrophy

Rare-disease drug firm BioMarin has finalised its purchase of muscular disease specialist Prosensa in a deal worth over $840 million. …

News
GSK image

GSK/Prosensa confirm orphan drug setback

September 23, 2013
Sales and Marketing GSK, MD, Prosensa, drisapersen

An experimental treatment by GSK and Prosensa for a rare type of muscle-degenerating disease has failed to meet its primary …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025